Salim Syed
Stock Analyst at Mizuho
(2.37)
# 2,549
Out of 5,072 analysts
76
Total ratings
42.62%
Success rate
0.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASMB Assembly Biosciences | Maintains: Outperform | $29 → $40 | $37.03 | +8.02% | 2 | Nov 20, 2025 | |
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $1.83 | +665.03% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $68.15 | +23.26% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $181.94 | -7.11% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $344.57 | -18.74% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $127.51 | -8.24% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $7.67 | +186.83% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $49.65 | +228.30% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $14.86 | +21.13% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $21.68 | +56.83% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $53.30 | +85.74% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $71.72 | -26.10% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.31 | +1,503.05% | 5 | Nov 16, 2022 |
Assembly Biosciences
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $37.03
Upside: +8.02%
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $1.83
Upside: +665.03%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $68.15
Upside: +23.26%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $181.94
Upside: -7.11%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $344.57
Upside: -18.74%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $127.51
Upside: -8.24%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $7.67
Upside: +186.83%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $49.65
Upside: +228.30%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $14.86
Upside: +21.13%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $21.68
Upside: +56.83%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $53.30
Upside: +85.74%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $71.72
Upside: -26.10%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.31
Upside: +1,503.05%